Imed Infinity 2025: GNX Bought Time, but Value Still Depends on Three Private Marks

Company Overview

Imed Infinity is not a medical device company and it is not a software company. It is a small public R&D partnership that holds a portfolio of digital health and medtech investments and tries to create value through portfolio uplift and eventual realizations. That distinction matters. In a report like this, the key questions are not revenue growth or gross margin at one operating company. The real questions are how much cash is actually left at the listed entity, how much of the reported value still rests on level 3 marks, and how much of that value can realistically reach public unitholders.

What clearly worked in 2025 was liquidity. The GNX exit and the rights offering lifted cash and cash equivalents from $884 thousand at the end of 2024 to $2.883 million at the end of 2025. There is no financial debt here, current liabilities are only $187 thousand, and the full-year loss narrowed to $192 thousand from $575 thousand in 2024. That bought the partnership time. That is the genuine improvement in the file.

But a shallow read can still miss the main point. This was not a full de-risking year. It was a year in which one realization and one equity raise refilled the treasury while 64% of the balance sheet still consisted of a private level 3 portfolio marked at $5.149 million. Inside that portfolio, Theranica, CytoReason, and Biobeat account for $4.292 million combined, or 83.4% of the total. So the active bottleneck is not overhead. The bottleneck is the partnership's ability to turn private marks into accessible value.

That friction is not theoretical. The partnership ended the year with more cash, but no distributable retained earnings. It asked the court to approve a distribution of up to $1 million through a capital reduction, and that process was then delayed because of a lawsuit filed against the partnership, the general partner, and the controlling shareholder in connection with a NIS 4.2 million loan given to the general partner. At the same time, the participation units remained on the main TASE list, but the preservation warning is still in place and will be tested again on June 30, 2026. In other words, even after the cash improvement, the story is still not clean.

What matters immediately:

• The 2025 improvement came mainly from the GNX exit and the rights offering, not from a broad rerating of the remaining portfolio.
• Three private holdings account for 83.4% of the portfolio, so the formal diversification is wider than the economic diversification.
• Theranica raised $35 million and Imed followed on, but the carrying value still relies on a PWERM framework with a 20% discount rate and a 2 to 3 year liquidity horizon.
• There is cash, but the path from cash to public-holder value is still constrained by the partnership's incentive structure, the profit test, and the legal process.

The economic map looks like this:

Events and Triggers

The GNX realization

The most important event in 2025 was not a valuation memo. It was hard cash. GNX was sold to Qiagen, with GNX as a whole priced at about $70 million in upfront cash plus a possible additional future component of up to $10 million. For Imed, the immediate consideration actually received amounted to $2,263,936, and another $28 thousand was received on November 13, 2025 as part of the future consideration component.

That matters in two ways. First, this is a real validation event. Not a model, not a mark, but actual cash received. Second, the same realization also removes GNX from the remaining portfolio. So the stronger treasury and the smaller loss do not mean the remaining portfolio became stronger. They mean one investment turned into cash.

That is the core distinction between created value and accessible value. In GNX, Imed proved it can get to a monetization event. But once GNX is removed from the picture, the remaining portfolio leans even more heavily on Theranica, CytoReason, and Biobeat.

Theranica and Biobeat received external validation, but not full value resolution

In December 2025, Theranica completed a cash Series D round of about $35 million. Imed invested an additional $458 thousand and ended up holding about 1.31% of Theranica's issued and paid-up share capital, or 1.13% on a fully diluted basis. On the surface, that should look clearly positive. The company attracted fresh capital, Imed kept its seat in the round, and there is now a better external anchor for value. But that is where the story needs more discipline.

At the end of 2024, Theranica was carried at $1.384 million. At the end of 2025, it was carried at $1.747 million. That looks like a $363 thousand increase. In practice, Imed injected another $458 thousand during the year, and the financial statement itself says the 2025 fair value movement was a decline of about $95 thousand. So the round preserved the position, but it did not translate into a full mark-up relative to the fresh cash that went in.

The same pattern is visible at Biobeat. The company completed a roughly $50 million Series B round at the end of December 2025. After the round, Imed's stake fell to 1.26%, and the carrying value fell by $239 thousand to $1.268 million. In plain English, the fact that a portfolio company raised money does not automatically mean Imed's economic value in that company went up.

Cynerio went out, Axonius came in

In August 2025, the sale of Cynerio to Axonius closed, and Imed received Axonius Series E-2 preferred shares instead of its Cynerio stake. The fair value of the Axonius position at year-end 2025 was $476 thousand, and the filing notes that about 12% of the consideration is expected to remain in escrow for 12 months for indemnification purposes. Again, this shows the gap between a strategic event and a liquid value event. Imed received a stake in a larger private company, not cash.

The Axonius mark relies on a company valuation of about $2.6 billion from the last fundraising round in March 2024, which also served as the basis for the exchange ratio. So this is not a liquidity trigger. It is a new private-mark exposure.

The exchange warning and the attempted distribution

At the beginning of 2025, the partnership received a warning from the exchange that it was not meeting preservation rules tied to minimum public holding value. It met the thresholds again at the June 30 and December 31, 2025 checkpoints and therefore remained on the main list. But the warning itself was not removed, and the next test date is June 30, 2026.

At the same time, on December 14, 2025, the partnership asked the court to approve a distribution of up to $1 million despite not meeting the profit test. As of December 31, 2025, it had no distributable retained earnings. On February 15, 2026, the required regulatory approvals for a capital reduction had been received, but the court paused the decision because of an objection by the third party that had filed the lawsuit. That is a material point because it sharpens the distinction between cash that exists and cash that can actually move to public holders.

Efficiency, Profitability and Competition

For a vehicle like Imed, "profitability" is not a gross margin story. It is a question of how much portfolio value remains after overhead, dilution, fundraising costs, and the gap between book value and actual monetization. That is why 2025 has to be read through two parallel statements: the full-year loss narrowed materially, but the remaining portfolio did not go through a broad-based revaluation upward.

What actually drove the 2025 result

In 2025, the partnership posted a positive fair value remeasurement of $226 thousand, compared with $41 thousand in 2024. That helped, but it was not the whole story. Total expenses were still $652 thousand, and the operating loss was still $426 thousand. The bottom line also benefited from net finance income of $234 thousand, mainly because of FX and interest on deposits.

The more revealing number appears in the half-year split. In the first half of 2025, Imed posted total comprehensive income of $391 thousand, driven mainly by a positive $657 thousand fair value remeasurement. In the second half, it posted a $583 thousand total comprehensive loss after a negative $431 thousand fair value movement. That is the key data point. A reader focused only on the full-year headline sees improvement. A reader who splits the year into halves sees a portfolio that is still volatile and still fragile.

The quality of the remaining portfolio

All of Imed's investments are level 3. That is not a footnote. It is the economic core of the balance sheet. At year-end 2025, the partnership's exposure to unlisted investments measured at fair value stood at $5.149 million. The filing lays out discount rates of 19% to 22% and expected liquidity timelines between half a year and 3.5 years depending on the asset.

In Theranica, for example, the value relies on PWERM, a 20% discount rate, and a projected liquidity event 2 to 3 years out. The standalone valuation report attached to the filing derives a $135 million equity value for Theranica, based on the December 2025 $35 million Series D round, and marks Imed's stake at $1.748 million. The sensitivity table shows that moving the discount rate between 18% and 22% shifts Imed's carrying value between $1.695 million and $1.803 million. That is not an extreme sensitivity. But it also does not answer the larger question, which is whether the assumed liquidity event actually arrives on that timeline.

From a competitive standpoint, Imed's value proposition is not about selling one product. It is about getting into the right companies early enough and supporting them until a round, a sale, or another monetization event. The filing itself argues that the Israeli tech environment improved in 2025 in terms of funding and exits, but it also stresses that geopolitical uncertainty and the sovereign-rating backdrop still make fundraising and financing less attractive. That means Imed faces two competitive tests at once: competition for new investments, and competition among its existing portfolio companies for capital and patience.

What the market may be missing

The easy mistake is to assume that Theranica's and Biobeat's fundraising rounds "validated" the whole portfolio. In reality, those rounds validate that the companies can still raise money. That matters. But it is not the same as proving value for a small public minority holder like Imed. Once the listed-entity layer is taken seriously, the real question is not only whether a company raised money, but on what terms, with what dilution, how much time was bought, and whether the next step is more likely to be liquidity or just another bridge.

Cash Flow, Debt and Capital Structure

The right cash bridge here is all-in cash flexibility

For Imed, the right framing is all-in cash flexibility. This is not a company with recurring operating cash generation that should be normalized with maintenance capex assumptions. It is an investment partnership. So the right question is how much cash remained after the year's actual cash uses.

The 2025 bridge is clear. The partnership started the year with $884 thousand in cash, used $340 thousand in operating cash flow, invested $466 thousand in portfolio companies, received $2.293 million from the GNX realization, raised $512 thousand in the rights offering, and ended the year with $2.883 million.

That is a real improvement. More importantly, the director report states explicitly that the partnership has not taken debt. There is no financial leverage burden here, only low current liabilities. The immediate financing pressure has clearly eased.

But the cash is still not fully free

This is the less comfortable part of the story. The partnership itself says that out of the roughly $2.9 million on hand, it intends to allocate $1 million to a dividend distribution and the rest to ongoing activity and possible additional portfolio support. In other words, if the capital reduction is eventually approved, cash would fall from $2.883 million to $1.883 million before the partnership even decides whether to support portfolio companies again. That is a decline of about 34.7%.

So the balance sheet is cleaner than the public-holder cash picture. There is cash, but it is already spoken for in three directions: portfolio support, a proposed return of capital, and a safety cushion against uncertainty in the private portfolio. That is why the sentence "the cash box has been replenished" is true but incomplete. The real question is how much of it is genuinely free.

The incentive structure matters for public-holder value

Management fees paid to the general partner are set at a semiannual 0.4% of total assets. In 2025, those fees were $82 thousand. The partnership also paid the general partner $40 thousand for assistance related to the rights offering. On top of that, the structure includes promote fees of 20% or 30% of net proceeds from realization events, subject to hurdle conditions. No such promote fees were paid in 2025, but the structure matters because it defines why gross asset value is not automatically the same as net value available to the public unitholder.

That is exactly where created value needs to be separated from accessible value. GNX created cash. But the path from future exits to public-holder return is still shaped by promote fees, management fees, the profit test, and capital-allocation decisions at the partnership level.

Outlook

2026 looks like a proof year. Not a breakout year. Not a reset year. A proof year. What has already been proven is that Imed can get at least one meaningful realization event and rebuild its cash buffer. What has not yet been proven is that the remaining portfolio can produce another such event, or at least enough external validation to make the market trust the marks.

Before looking forward, four points frame 2026:

• Theranica, CytoReason, and Biobeat now drive the story. Without external progress in at least one of them, the reading on Imed is hard to upgrade.
• The cash balance looks adequate against corporate overhead, but less so against aggressive follow-on support across several holdings.
• Legal clarity around the lawsuit and the capital reduction would change the discussion around value accessibility more than any minor accounting adjustment.
• The June 30, 2026 preservation-rule test is a real market trigger because it affects actionability, not just theory.

What has to happen inside the portfolio

Theranica completed a large D round, and its valuation attachment includes additional operating and capital-structure data. That gives it a better evidentiary base than a purely abstract mark. But from Imed's perspective, what needs to happen next is not simply another private round. It is an event that clearly advances monetization, or at least provides an external anchor stronger than a discounted exit model.

At Biobeat, the $50 million round proves access to capital, but the $239 thousand decline in Imed's carrying value is a reminder that a funding round can protect the company more than it protects a small minority holder. If Biobeat converts that round into real commercial progress, Imed benefits. If the round mainly bought time, the quality of the story will remain mixed.

CytoReason is the quieter holding, but that may be exactly why it matters. Its carrying value only increased by $42 thousand, yet it remains a more than $1.2 million position. It is not the headline name, but it is clearly one of the holdings that can stabilize the thesis if it keeps delivering external proof points.

Where the picture can weaken again

Polaris is the reminder that not every digital-health and life-science story gets the same runway. The company itself said it had moved to a reduced operating mode, raised only about $500 thousand in February 2025 through an expansion of existing bridge financing, and expected that cash to last only until the end of the third quarter of 2026. The filing explicitly says there is a material risk to the continuation of Polaris and therefore a risk that Imed's investment could be wiped out.

Nanomedic also shows how dilution can eat into upside. Imed's ownership fell from 3.4% to roughly 0.9%, and while the carrying value increased to $151 thousand, this is still a small position. Anyone looking for another near-term step change in the Imed story is unlikely to get it from there.

What the market is likely to measure next

In the near term, the market is not likely to spend much time on a broad digital-health narrative. It will probably focus on three simple questions:

1. Does one of the three core holdings deliver an external event that strengthens confidence in value?
2. Can the proposed $1 million distribution actually get out of the company?
3. Do the units move fully out of the preservation-warning shadow?

If the answer turns positive on all three, the market reading can change quickly. If not, 2025 will likely look in hindsight like a pause year rather than a structural turning point.

Risks

Concentration and level 3 mark risk

This is the first risk, not the second one. Three holdings represent more than 83% of the portfolio. All investments are level 3. Fair value in private companies is not tested every day in an open market. So even without debt, there is still estimation risk and valuation volatility.

Future funding risk at the portfolio companies

The filing repeatedly flags the difficulty portfolio companies may face in raising future capital as a major sector risk. That is not a tail risk. It is part of the model. One successful realization like GNX does not remove the need for the rest of the portfolio to keep finding external capital.

Governance and value-access risk

The lawsuit around the loan to the general partner, the allegation that a pledge obligation was breached, and the fact that the court paused the capital-reduction decision all create a layer of friction the market does not like. Even if the partnership is eventually dismissed from the case and no provision is recorded, the simple fact that the first capital-return move ran into a legal obstacle is enough to show how vulnerable the structure can be.

Market and listing actionability risk

The current market capitalization is about NIS 7.7 million. That is extremely small for a public vehicle, and together with the preservation warning it creates an actionability constraint. That does not mean there is no value in the report. It means the market will likely demand much stronger proof before it is willing to capitalize that value cleanly.

Conclusions

The current thesis on Imed is fairly clean: there is more time now, but not yet full proof. GNX gave the treasury room to breathe, there is no financial debt, and the portfolio still contains three holdings that can create meaningful value. The main blocker is that this value still has not passed often enough through real market events, while the first planned cash return is also stuck in a legal process. In the short to medium term, the market will likely focus on whether another external validation event arrives and whether the listing and capital-reduction frictions are resolved.

Current thesis: Imed moved from immediate liquidity pressure to a realization test.

What changed: In 2025 the story shifted from "is there enough cash to survive?" to "is there enough external proof for the market to trust the portfolio marks?"

Counter thesis: After the GNX exit, with $2.883 million in cash and no financial debt, one more strong event in Theranica, CytoReason, or Biobeat could quickly widen the gap between current market value and portfolio value.

What could change the market reading: legal clarity that enables an actual cash distribution, alongside an external validation event at one of the three core holdings.

Why this matters: Imed is a classic case study in the gap between value created on paper and value that can actually reach public holders.

Over the next 2 to 4 quarters, Imed needs three things: another external proof point for one of the core holdings, clarity on whether cash can actually be returned, and a full move out of the exchange-warning zone. If that happens, 2025 will look like a successful bridge year. If not, the market will quickly return to the older and tougher question: how much of this reported value can really be realized.